uniQure (QURE) – AMT-191 Fabry data update, Huntington’s regulatory reset and AAV5 platform risk map

1. Executive summary – why this Fabry update matters now

The February 6, 2026 update on AMT-191 for Fabry disease lands at a delicate moment in the uniQure story. On the one hand, the company has just shown that a single AAV5-based gene therapy can push α-Gal A enzyme activity far above the normal range, maintain those supraphysiologic levels for more than a year in the longest-treated patient and support withdrawal from bi-weekly enzyme replacement therapy (ERT) in more than half of the treated cohort so far. On paper, this is exactly what gene therapy is supposed to do: convert a chronic infusion business into a one-time intervention that normalises – or even overshoots – the missing enzyme, while holding key substrate biomarkers in check.

On the other hand, the same dataset contains a warning light. Two patients in the mid-dose cohort developed asymptomatic Grade 3 liver enzyme elevations, deemed dose-limiting toxicities by the Independent Data Monitoring Committee. In line with the protocol, uniQure has paused additional dosing in the mid- and high-dose cohorts while it analyses the signal and optimises the risk–benefit profile. This pause arrives on top of a more structural source of uncertainty: the U.S. Food and Drug Administration (FDA) has already told the company that Phase I/II data in Huntington’s disease are “currently unlikely” to serve as the primary evidence for a Biologics License Application (BLA) for AMT-130, forcing a reset of expectations around timing and design of the pivotal program.

The net result is a highly asymmetric setup. From a scientific and platform standpoint, uniQure arguably has one of the most validated AAV5 franchises in the field, as illustrated by five-year HEMGENIX data in hemophilia B showing durable factor IX expression and continued freedom from prophylaxis in the vast majority of treated adults. From an equity and risk-management standpoint, however, the investment case is dominated by two intertwined questions: whether AMT-130 can still find an accelerated or hybrid regulatory path in Huntington’s after the recent feedback, and whether AMT-191 can keep its extremely strong biological signal while reducing the incidence of dose-limiting hepatotoxicity to levels regulators and payers can live with.

This report walks through those questions program by program, then re-aggregates them into a balance-sheet, catalyst and risk map. It deliberately avoids price targets or trading recommendations. The objective is to frame what has actually changed with the Fabry update, how it interacts with the Huntington narrative, and what a realistic “watch list” should include for the next 12–24 months if you are following QURE from the perspective of clinical data, regulatory dialogue and corporate runway rather than short-term price swings.

2. Company and AAV5 platform – from HEMGENIX to multi-program risk

uniQure is built around a single core competency: the design, manufacturing and long-term follow-up of adeno-associated virus serotype 5 (AAV5) gene therapies for severe rare diseases. The company’s most visible validation comes from HEMGENIX, a one-time intravenous treatment for adults with hemophilia B. Five-year follow-up data from the pivotal HOPE-B study show sustained factor IX activity in the mid-30% range on average, with approximately 94% of participants remaining free from continuous prophylaxis infusions five years after dosing, and no new major safety concerns emerging beyond the early post-infusion window. These data have now been published in a leading medical journal and presented at a major hematology congress, moving the debate around AAV5 from “can it work” to “how do we generalise and price it responsibly”.

Rather than running a large in-house commercial organisation around HEMGENIX, uniQure has effectively monetised its platform via a licensing and manufacturing arrangement, while redirecting its internal resources towards central nervous system and lysosomal storage indications. The current clinical and pre-clinical portfolio spans:

AMT-130 for Huntington’s disease, an intrastriatal gene therapy intended to lower huntingtin and slow progression in a relentlessly degenerative condition with no disease-modifying options today. Early-phase data, together with external controls derived from the ENROLL-HD dataset, formed the basis for an initially supportive FDA stance on an accelerated approval strategy, before the more cautious feedback delivered in late 2025.

AMT-191 for Fabry disease, the focus of this report, which uses AAV5 to deliver a chimeric α-Gal A transgene aimed at achieving high and durable enzyme activity across tissues, including heart and kidney, with the potential to obviate regular enzyme-replacement infusions.

AMT-260 for refractory mesial temporal lobe epilepsy (MTLE), where early case-study data from the first treated patient showed a more than 90% reduction in seizure frequency with no serious safety events through the first five months of follow-up. And AMT-162 for SOD1-positive ALS, which is still in early clinical development with initial data expected in 2026.

The common denominators across these candidates are the vector, the manufacturing platform and a risk-sharing balance sheet that still relies heavily on the durability of HEMGENIX cash flows and external funding events to support multiple parallel development streams. For Fabry and Huntington in particular, the story is less about whether AAV5 works per se and more about how precisely it can be dosed, monitored and framed statistically to satisfy both regulators and clinicians in diseases with complex natural histories.

3. Fabry disease 101 – why α-Gal A and lyso-Gb3 really matter

Fabry disease is an X-linked lysosomal storage disorder caused by a deficiency of the enzyme α-galactosidase A (α-Gal A). When α-Gal A is missing or severely reduced, glycosphingolipids such as globotriaosylceramide and its derivative globotriaosylsphingosine (lyso-Gb3) accumulate in multiple tissues, damaging kidneys, heart, nervous system, eyes and skin over time. Clinically, this translates into a spectrum that ranges from childhood-onset pain crises and angiokeratomas to progressive cardiomyopathy, arrhythmias, stroke and renal failure in adulthood.

Current standard of care centres on bi-weekly intravenous enzyme replacement therapy. While ERT can reduce substrates and improve some symptoms, it is limited by incomplete cross-correction in key organs, infusion burden, anti-drug antibodies and suboptimal impact on long-term renal and cardiac outcomes for many patients. Oral chaperone therapies exist for selected genotypes but are not broadly applicable.

From a trial-design perspective, this pathophysiology implies that two biomarker axes matter most in early- and mid-stage Fabry programs:

First, the level and durability of α-Gal A activity itself. Achieving enzyme levels in the normal range might be enough to reduce substrate accumulation, but the rationale behind AMT-191 is more aggressive: drive α-Gal A to supraphysiologic levels, then trust that the system will find a new steady-state in which toxic substrates are efficiently cleared from heart and kidney, rather than just partially controlled in plasma.

Second, the behaviour of lyso-Gb3 in plasma and, ideally, in tissue over time. Lyso-Gb3 is an accepted biomarker of disease burden and has been used across multiple Fabry programs as a proxy for long-term risk, even if correlation with hard clinical endpoints is complex. A gene therapy that produces spectacular α-Gal A peaks but fails to keep lyso-Gb3 flat or trending down would not be compelling. Conversely, a gene therapy that normalises or stabilises lyso-Gb3 while allowing patients to discontinue ERT without rebound would be highly attractive from both a medical and a health-economics standpoint.

4. AMT-191 Phase I/IIa – design, cohorts and the February 2026 update

The Phase I/IIa program for AMT-191 is a multi-center, open-label trial in adult male patients with Fabry disease conducted in the United States. The design is relatively classic for a first-in-human AAV program: three dose cohorts (2×10¹³, 4×10¹³ and 6×10¹³ genome copies per kilogram) with at least three patients per cohort, intravenous infusion, continued ERT until pre-specified withdrawal criteria are met, and a minimum of 24 months of planned follow-up.

Importantly, patients are not excluded based on pre-existing neutralising antibodies to AAV5, a design choice that mirrors the company’s experience with HEMGENIX and aims to make the program more representative of real-world Fabry populations. The primary objectives are safety and tolerability; key exploratory endpoints include α-Gal A activity over time, plasma lyso-Gb3 dynamics and the feasibility of withdrawing ERT without loss of disease control.

As of the January 8, 2026 data cutoff, 11 patients had been treated across the three dose levels. The headline findings can be summarised along three axes:

Enzyme activity. All 11 patients showed elevated α-Gal A activity compared to the mean normal level (3.57 nmol, with a normal range of 1.38–8.66). At the lowest dose, activity ranged from 0.34- to 82.2-fold above the mean normal; at the mid dose, from 1.6- to 312.5-fold; and at the highest dose, from 27.7- to 223.7-fold. These are extraordinarily high multiples by the standards of enzyme-replacement medicine, and importantly they were maintained over time across the available follow-up, which spans from roughly four months in the most recently treated mid-dose patient to more than one year in the longest-followed high-dose participant.

ERT withdrawal and lyso-Gb3. Six of the 11 treated patients had met pre-specified withdrawal criteria and discontinued ERT by the cutoff date. Across all dose cohorts, plasma lyso-Gb3 levels were described as stable post-dose, regardless of whether patients remained on ERT or not. While the update does not yet provide detailed numerical trajectories or organ-specific imaging, maintaining stable lyso-Gb3 in the face of supraphysiologic α-Gal A and ERT withdrawal is directionally aligned with the program’s objective: move enzyme activity into a new range, then use substrate behaviour to confirm that this new steady-state is not only tolerable but beneficial.

Safety profile. Overall, AMT-191 continues to show what the company calls a “manageable” safety profile, but the details matter. At the two lower dose levels, no serious adverse events were reported as related to AMT-191. However, two patients at the 4×10¹³ gc/kg dose experienced asymptomatic Grade 3 elevations in liver enzymes. These events were confirmed as dose-limiting toxicities by the Independent Data Monitoring Committee, and per protocol, uniQure has paused additional dosing in both the mid- and high-dose cohorts pending further evaluation. At the 6×10¹³ gc/kg dose, no new serious adverse events beyond those previously reported were observed; those earlier events included two unrelated SAEs, two related SAEs (chest pain and increased troponin) and one possibly related SAE (leptomeningeal enhancement), as well as a Grade 3 liver enzyme elevation that resolved with corticosteroids.

Taken together, this is the profile of a program with very strong biological activity and a non-trivial but apparently steroid-responsive hepatotoxicity signal that now needs to be fully characterised. The decision to pause further dosing at higher levels is not unusual in dose-finding gene therapy studies; what will matter over the next 12–18 months is how the company integrates this safety information into an eventual pivotal-dose selection, and whether regulators view the risk–benefit ratio as acceptable in the context of Fabry’s progressive multi-organ burden.

5. Safety, immunogenicity and the implications of a mid/high-dose pause

Liver enzyme elevations are a familiar feature of systemic AAV gene therapy. In many haemophilia and metabolic programs, short courses of corticosteroids have effectively controlled transaminase flares, with patients retaining clinically meaningful expression of the therapeutic transgene. From that standpoint, the Grade 3 alanine aminotransferase (ALT) elevations seen with AMT-191 are not intrinsically surprising. What matters is the frequency, severity and reversibility of such events, and whether they correlate with any loss of efficacy or more serious hepatic pathology.

In the AMT-191 program, the available information suggests that the affected patients responded to corticosteroid therapy and remain under follow-up without new serious complications. That is reassuring at an individual-patient level. However, the formal classification of these events as dose-limiting toxicities means that the mid-dose level cannot simply be rolled forward unmodified into later-stage development. The protocol-mandated pause in mid- and high-dose dosing is essentially a chance to step back and reassess whether the current dose spacing is optimal or whether a slightly lower target dose, tighter steroid prophylaxis or refined inclusion criteria could preserve the biological upside while reducing the probability of Grade 3 events to a level that satisfies both investigators and regulators.

Immunogenicity adds another layer of complexity. Fabry patients can have pre-existing antibodies to AAV5, and they are also chronically exposed to exogenous enzyme through ERT, which can shape their immune environment in ways that might interact with the gene therapy. The company’s decision not to exclude AAV5-seropositive individuals is a bet that AAV5’s track record in HEMGENIX – where efficacy was preserved even in the presence of neutralising antibodies in some cases – will generalise here as well. Early data do not suggest catastrophic loss of expression in the presence of antibodies, but the longer-term immunological footprint of sustained supraphysiologic α-Gal A expression still needs to be mapped carefully, especially in organs such as kidney and heart.

For now, the pause in mid/high dosing should be read less as a red flag on the feasibility of AMT-191 and more as a standard step in calibrating where the optimal therapeutic window sits. The crucial question is whether there exists a dose (or dosing plus steroid regimen) that delivers enough enzyme activity and ERT independence to justify the risk, without generating an incidence of Grade 3 hepatotoxic events that would make regulators uncomfortable in a chronic but treatable condition. The preliminary answer looks cautiously positive, but only richer longitudinal data and detailed protocol updates will settle that debate.

6. AMT-130 for Huntington’s disease – accelerated no more?

If AMT-191 is the engine of the Fabry optionality, AMT-130 remains the emotional core of the uniQure story. Huntington’s disease (HD) is a devastating autosomal-dominant neurodegenerative disorder, and the prospect of a one-time gene therapy that could meaningfully slow its course has attracted intense scientific and patient-community attention. Throughout 2024 and early 2025, uniQure communicated a narrative in which three-year data from its Phase I/II trials, combined with a carefully constructed external control arm from ENROLL-HD, could support an accelerated approval BLA as early as the first quarter of 2026.

That narrative reached its high point in mid-2025, when the company reported “alignment” with the FDA on the statistical analysis plan and Chemistry, Manufacturing and Controls (CMC) requirements for such a BLA. At that time, the plan envisaged a primary efficacy analysis based on three-year change in the composite Unified Huntington’s Disease Rating Scale (cUHDRS) in high-dose AMT-130 recipients versus propensity-score matched external controls, with additional sensitivity analyses using propensity-score weighting. In parallel, the company was conducting a Process Performance Qualification campaign leveraging knowledge from the HEMGENIX manufacturing process.

However, in early November 2025, the tone changed. After a pre-BLA meeting held on October 29, the FDA’s final minutes stated that the Phase I/II dataset is currently unlikely to provide the primary evidence needed to support a BLA submission for AMT-130. In plain language, regulators were no longer comfortable with the idea that an external control-based comparison from a relatively small single-arm trial should form the backbone of a marketing application in such a complex neurodegenerative disease. uniQure responded by announcing that it would urgently request a follow-up meeting in the first quarter of 2026, and in January 2026 disclosed that a Type A meeting had been scheduled specifically to revisit the data package and regulatory pathway.

This does not mean that AMT-130 has “failed” or that the data are negative; public communications to date have remained broadly supportive of a disease-modifying signal. Rather, it means that the regulatory bar for using early-phase data and external controls as the primary foundation for approval has moved, likely in response to the broader field’s experience with accelerated approvals and post-marketing uncertainty in neurodegenerative indications. For uniQure, the question now is whether it can craft a hybrid design – for example, a relatively small randomised or controlled confirmatory study anchored in the existing dataset – that preserves a viable timeline while answering the FDA’s concerns more explicitly.

7. Financial position – how much time does QURE really have?

The most granular public view of uniQure’s balance sheet comes from the second-quarter 2025 earnings release. As of June 30, 2025, the company reported approximately $377 million in cash, cash equivalents and investment securities, up from about $368 million at year-end 2024, largely thanks to net proceeds of roughly $80.5 million from a follow-on equity offering in January–February 2025. Management explicitly guided that this cash position should be sufficient to “fund operations into the second half of 2027”, including the planned launch of AMT-130 in their base-case scenario.

On the income-statement side, second-quarter 2025 revenue was about $5.3 million, down from $11.1 million in the same period of 2024, reflecting lower collaboration and contract manufacturing contributions, partially offset by licence revenue. Research and development expenses were approximately $35.4 million for the quarter, with selling, general and administrative expenses at around $13.5 million. The net loss for the quarter was roughly $37.7 million, or $0.69 per basic and diluted share, an improvement versus the $56.3 million net loss in the prior-year period.

Two aspects of this financial profile are particularly relevant for interpreting the Fabry and Huntington updates. First, the runway guidance into the second half of 2027 was articulated before the FDA pushed back on the idea of a Phase I/II-based BLA for AMT-130. If the Huntington program now requires an additional controlled study, that will inevitably consume more capital than originally planned, unless offset by pipeline reprioritisation or external funding. Second, the company’s cost base reflects a multi-program, multi-indication strategy: AMT-130, AMT-191, AMT-260 and AMT-162 are all moving in parallel, and HEMGENIX economics, while helpful, are not yet at a scale that can cross-subsidise everything without careful discipline.

Viewed through a risk-management lens, the combination of a reasonably long runway, a proven commercial asset via partnership and several late-stage-capable programs is attractive. Viewed through the more volatile lens of small-cap biotech trading, the same configuration can produce abrupt sentiment swings when any one program’s path deviates from the expected script, as seen with the November 2025 regulatory update on AMT-130. For Fabry, this means that each incremental data cut and every nuance in how the dose-limiting events are reported may feed directly into perceptions of whether the company needs to raise capital sooner than previously anticipated.

8. Competitive landscape – where AMT-191 and AMT-130 might fit

In Fabry disease, uniQure is not operating in a vacuum. The therapeutic landscape already includes multiple ERT products and at least one oral chaperone therapy, and there are other gene-therapy and next-generation approaches in development. Broadly, the competition can be grouped into three categories: improved enzyme replacement, substrate-reduction or chaperone approaches, and gene-based interventions. AMT-191 squarely belongs to the latter.

The differentiating thesis for AMT-191 rests on three pillars. First, its ability to drive α-Gal A activity well above the normal range in a dose-dependent fashion, potentially enabling deeper substrate clearance in key organs. Second, the potential to maintain stable lyso-Gb3 while withdrawing ERT entirely in a meaningful proportion of patients, which would redefine the treatment experience and cost structure. Third, the use of AAV5 and a chimeric transgene design informed by the company’s experience in other indications.

Against that backdrop, competitors may pursue strategies that favour lower but steady enzyme levels with fewer immunologic concerns, or that combine ERT with adjunctive therapies to improve organ penetration. The net clinical value of AMT-191 will ultimately be judged by its ability to translate spectacular enzyme over-expression into tangible, sustained improvements in renal, cardiac and neurological outcomes, with an acceptable safety profile. Until longer-term organ-level data emerge, the program will trade more on mechanistic promise than on hard outcomes.

In Huntington’s disease, AMT-130 faces a different kind of competition – not so much from other gene therapies (although there are RNA-based and vector-based programs in development) as from the natural scepticism regulators have developed after several waves of neurodegenerative drug approvals with complex post-marketing narratives. The bar for accepting external controls and surrogate endpoints has risen. Any future AMT-130 pathway is likely to be benchmarked against emerging standards for HD trial design, which may include greater emphasis on randomisation, composite functional endpoints and multi-year follow-up.

9. Catalyst map – what actually moves the story from here

Over the next 12–24 months, the uniQure narrative is likely to pivot around a handful of concrete inflection points rather than a constant drip of minor updates. From a Fabry/Huntington-centric perspective, the most relevant buckets are:

For readers tracking uniQure within a broader small-cap biotech watchlist, these are the points worth highlighting in any personal catalyst calendar. Day-to-day price swings driven by general risk-on/risk-off sentiment or broader gene-therapy headlines are often noise around this core.

10. Management and execution – strengths and pressure points

uniQure’s leadership team has accumulated a decade-plus of experience in shepherding AAV therapies from pre-clinical design through long-term follow-up and manufacturing scale-up, culminating in the approval and rollout of HEMGENIX. That track record is non-trivial; many gene-therapy stories never make it past proof-of-concept, let alone to five-year commercial follow-up.

At the same time, the recent regulatory communication on AMT-130 and the dose-limiting hepatotoxicity observations in AMT-191 highlight the inevitable friction that arises when pushing aggressive development timelines in complex diseases. Crafting an accelerated approval strategy around Huntington’s based on external controls was always going to be ambitious. The fact that the FDA initially appeared supportive and then stepped back underscores how dynamic the regulatory environment remains, especially in neurodegeneration.

Execution-wise, the company’s ability to maintain a robust cash balance through opportunistic capital raises and partnering, while advancing four clinical programs in parallel, speaks to a willingness to manage the balance sheet proactively. The key test over the next two years will be whether that discipline extends to prioritising among programs and adjusting spend as the regulatory and competitive landscapes become clearer, rather than trying to move everything at once in the same way it might have in a looser capital market.

11. Sentiment – what retail traders and patient communities are actually saying

Social platforms offer a noisy but instructive window into how non-professional market participants and patient communities perceive the uniQure story. In Huntington’s-focused forums and sub-communities, the tone is a mix of genuine hope and growing impatience. Many posts highlight the absence of any approved disease-modifying therapies for HD and view AMT-130 as one of the few credible attempts to change that. Others, especially after the FDA’s November 2025 feedback, express concern that timelines may slip by years, with all the human and financial consequences that implies.

On a major social-trading platform, QURE has alternated between periods where it is framed as a potential multi-bagger – especially around positive regulatory headlines such as Breakthrough Therapy designation for AMT-130 – and periods of sharp sentiment deterioration when expectations are not met. Following the December 2025 regulatory update, for example, sentiment indicators shifted from neutral or bullish to more cautious or outright bearish even though the long-term story had not fundamentally changed; what changed was the perceived path and timeline to monetisation.

On X, self-identified biotech enthusiasts and long-term investors often describe QURE as a leading or even “the” leading player in AAV-based gene therapy, pointing to the combination of HEMGENIX validation and a diversified pipeline. Some highlight the Fabry data as another proof-point that AAV5 can deliver overshooting enzyme expression safely when managed properly. Others raise technical questions about endpoint selection, statistical design and the practicalities of long-term follow-up in neurodegeneration. It is worth emphasising that these are views from individual traders and commentators, not formal research or regulated investment advice.

Overall, the social-media picture is one of high conviction in the science among a small but vocal group of followers, coupled with high sensitivity to news flow and a tendency to extrapolate single headlines into broad narratives about “approval guaranteed” or “story broken”. Any serious risk-management framework for following QURE should treat this sentiment stream as a source of colour, not as a decision driver.

Sentiment section based on public posts and aggregated indicators from Reddit, X (Twitter) and retail trading platforms. These reflect opinions of non-professional participants and should not be treated as investment research.

12. Key risks – what can go structurally wrong

Any deep dive on uniQure needs an explicit risk map. At a high level, the main structural risks include:

Regulatory risk in Huntington’s. The shift in FDA posture regarding AMT-130 means that the company can no longer assume that Phase I/II data plus external controls will be enough for approval. If the eventual regulatory path requires a large, lengthy and expensive controlled trial with conventional endpoints, the economics and timeline of the program could change materially versus earlier expectations.

Safety and dosing risk in Fabry. While the hepatotoxicity signal seen with AMT-191 appears manageable so far, there is no guarantee that larger datasets will not reveal more frequent or severe events. If regulators judge the risk–benefit ratio unfavourable at higher doses, the company may be forced to settle for lower enzyme targets, potentially reducing the clinical and commercial differentiation of the program.

Manufacturing and CMC risk across programs. AAV gene therapy is inherently complex to manufacture at scale, and the company’s ability to leverage HEMGENIX process knowledge does not eliminate the possibility of CMC-related delays, especially as regulators scrutinise vector integrity, potency assays and long-term safety more closely.

Financing and dilution risk. Although the current cash runway appears to extend into the second half of 2027 based on previous guidance, any upward revision in development costs or delay in key milestones could necessitate additional funding. For a small-cap biotech, such funding often comes via equity offerings or structured deals that can be dilutive.

Competition and pricing risk. In both Fabry and Huntington’s, the value proposition of a one-time gene therapy will be benchmarked against evolving standards of care, including improvements in chronic therapies and any competing gene-based or RNA-based approaches. Payers may push back on pricing or demand stringent outcomes-based contracts, affecting realised economics even if approvals are obtained.

13. Scenarios – a practical way to frame upside and downside

Instead of a single point forecast, it can be more useful to think in terms of a few stylised scenarios that capture the interaction between Fabry, Huntington’s and the company’s financial position. The following scenario grid is not a valuation model; it is a simple qualitative framework for organising expectations.

Reality will likely fall somewhere between these extremes, and may shift over time as data accumulate. The value of this scenario framing is not in predicting which one will materialise, but in making it easier to reinterpret new information quickly: a given piece of news can be slotted into the scenario that it nudges the story towards, rather than evaluated in isolation.

14. Final remarks – how to read this report

This deep dive has focused deliberately on what can be supported by official filings, company press releases and high-quality news sources, supplemented by an explicit look at retail and patient sentiment on open platforms. It is not a recommendation to buy, sell or hold any security, nor does it attempt to optimise entries, exits or position sizing. Its purpose is to offer a coherent map of how the Fabry AMT-191 update interacts with the broader uniQure story, particularly the Huntington’s program and the company’s financial runway.

For readers following multiple small-cap biotech names, the key takeaway is that QURE sits at the intersection of a validated platform, a complex regulatory dialogue and a non-trivial but manageable balance sheet. The upside case is that Fabry and Huntington eventually crystallise into durable, cash-generating franchises supported by long-term safety and efficacy data, with HEMGENIX as an anchor. The downside case is that regulatory, safety or financing frictions prevent that potential from fully materialising within the current cycle.